Technology Transfer

This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and provides a review and analysis of the existing body of knowledge concerning the role of IPRs.

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have collaborated on a new report that builds upon the findings in BVGH’s previous analysis, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.

While the U.S. leads in the area of biotechnology, there is no guarantee this competitive edge will continue.

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

The purpose of this survey was to examine the extent and importance of technology transfer and licensing activity involving biotechnology companies.

BIO released a survey on licensing trends between universities and companies.

The study provides first-of-its-kind data on the importance of university/industry research and development partnerships to the U.S. economy.

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

This side-event, organized by the Biotechnology Industry Organization (BIO) and cosponsored by the Association of University Technology Managers (AUTM), provided an overview on the key elements at play in establishment an enabling environment for transfer of technology to support the full implementation of CBD objectives and priorities.

February 14 2012
BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission.
April 7 2011
The House Subcommittee on Healthcare and Technology held a hearing on The Creating Jobs Through Small Business Innovation Act of 2011, a bill that would reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which help fund small innovative companies on the brink of new technologies and discoveries.
May 25 2010
The Biotechnology industry Organization appreciates the opportunity to respond to the Request for Information issued by the Office of Science and Technology Policy and the National Economic Council on Commercialization of University Research.
July 1 2009
Information on the Government’s Right to Assert Ownership Control over Federally Funded Inventions
May 15 2009
On behalf of BIO's member companies, we appreciate the opportunity to comment on the recently issued public consultation draft report on "Gene Patents and Licensing Practices and Thier Impact on Patient Access to Genetic Tests"
June 21 2012
The Biotechnology Industry Organization (BIO) released a report on the significant economic impact of university and non-profit institution patent licensing on the U.S. economy.
April 7 2011
Today, the House Subcommittee on Healthcare and Technology will hold a hearing on The Creating Jobs Through Small Business Innovation Act of 2011, a bill that would reauthorize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, which help fund small innovative companies on the brink of new technologies and discoveries.
July 30 2008
Small businesses that are majority-backed by venture capital, many of which are producing biotech therapies and cures, will be eligible for a portion of Small Business Innovation Research (SBIR) grants under a bill reported out of the Senate Committee on Small Business today. The bill reauthorizes the SBIR program for 14 years.
September 20 2006
The Milken Institute study released today entitled “Mind-to-Market: A Global Analysis of University Biotechnology Technology Transfer and Commercialization” reaffirms the critical role of technology transfer in the development of the biotechnology industry worldwide, said Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood.
May 30 2002
The Biotechnology Industry Organization’s (BIO) annual meeting, BIO 2002 in Toronto, will feature a Technology Transfer Forum that will bring science and business together to speed commercialization of basic technology into useful consumer products.